GILD News Alert Gilead Sciences (GILD) 101.21 01/12/2015 16:

New Post Public Reply Private Reply Replies (0) Message Board

Jan 12, 2015 at 5:16 PM

Gilead Sciences (GILD) 101.21 $GILD

Gilead Sciences to Present at the 33rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 13
Business Wire - 15 mins ago
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that its corporate presentation will be webcast from the 33rd Annual J.P. Morgan Healthcare Conference in San Francisco.
JPM: 58.83 (-0.51), GILD: 101.21 (-1.00)

Abbvie Retreats On Gilead, Anthem Deal. Buying Opportunity?
Shock Exchange - at Seeking Alpha - 2 hrs 28 mins ago

GILD: 101.21 (-1.00), ABBV: 65.76 (-0.02)

Prime Therapeutics Breaks from Competition, Strikes Deals to Prefer both Harvoni, Viekira Hepatitis C Drugs
PR Newswire - Mon Jan 12, 1:00PM CST
People with Hepatitis C who are served by pharmacy benefit manager Prime Therapeutics LLC (Prime) will now have greater support for the treatment recommended by their physician. This is a result of new agreements between Prime and pharmaceutical companies Gilead Sciences and AbbVie. Beginning immediately, the agreements place both Gilead's Harvoni® and AbbVie's Viekira Pak® on Prime's preferred drug list (formulary), meaning members can more easily get the medicine they need to feel better and live well.
GILD: 101.21 (-1.00)

Midday Glance: Biotechnology companies
AP - Mon Jan 12, 12:23PM CST
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.:
GILD: 101.21 (-1.00), AMGN: 156.22 (+0.49), CELG: 117.00 (+3.33)

Earnings Season Kicks Off Tonight: Here's What To Expect
Leigh Drogen - at Seeking Alpha - Mon Jan 12, 11:58AM CST
Earnings season unofficially kicks off today after the closing bell when Alcoa (NYSE: AA ) releases results for the fourth quarter. Current estimates paint a picture of two earnings seasons in a couple of regards. Yes, profit growth is expected to...
FDX: 172.57 (-0.09), NKE: 95.86 (-0.13), C: 50.38 (-0.40), BAC: 16.68 (-0.30), WFC: 52.05 (-0.63), UPS: 109.64 (+0.04), T: 33.49 (+0.09), AA: 16.17 (+0.06), GS: 185.07 (-2.28), JPM: 58.83 (-0.51), GILD: 101.21 (-1.00), MCD: 93.01 (-0.20), VZ: 47.08 (+0.32), AAPL: 109.25 (-2.76), YUM: 72.91 (-0.55)

Value Investing Strategy For Biotech
Henry Wolfe - at Seeking Alpha - Mon Jan 12, 11:57AM CST

CARA: 10.99 (+0.04), BLCM: 31.33 (-0.42), GILD: 101.21 (-1.00), KITE: 82.35 (+3.21), CLDX: 19.03 (-0.08), CALA: 22.86 (-0.78), AGIO: 131.55 (+3.43)

I'm Expecting Some Very Positive News Flow From Gilead
Brian Nelson - at Seeking Alpha - Mon Jan 12, 10:55AM CST

JNJ: 104.58 (-0.36), ABT: 45.58 (+0.38), VRTX: 118.31 (-3.90), ESRX: 83.08 (-1.82), GILD: 101.21 (-1.00), ACHN: 14.64 (+0.08), MRK: 62.30 (-0.26), CVS: 97.20 (-0.72), ABBV: 65.76 (-0.02), ENTA: 49.41 (-0.70)

Gilead Strikes Hep-C Deal With Anthem. Stock Remains Strong Buy
Shock Exchange - at Seeking Alpha - Mon Jan 12, 10:31AM CST

ANTM: 128.83 (-0.97), GILD: 101.21 (-1.00), ABBV: 65.76 (-0.02)

Earnings Season Kicks Off Tonight: Here’s What to Expect
ESTMZ - Mon Jan 12, 10:12AM CST
Earnings season unofficially kicks off today after the closing bell when Alcoa releases results for the fourth quarter. Current estimates paint a picture of two earnings seasons in a couple of regards. Yes, profit growth is expected to continue...
FDX: 172.57 (-0.09), T: 33.49 (+0.09), AA: 16.17 (+0.06), GS: 185.07 (-2.28), JPM: 58.83 (-0.51), GILD: 101.21 (-1.00), C: 50.38 (-0.40), WFC: 52.05 (-0.63), BAC: 16.68 (-0.30), VZ: 47.08 (+0.32), UPS: 109.64 (+0.04)

Early Glance: Biotechnology companies
AP - Mon Jan 12, 9:45AM CST
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.:
GILD: 101.21 (-1.00), AMGN: 156.22 (+0.49), CELG: 117.00 (+3.33)

Today's Market: Pharma And Biotech M&A Start 2015 With A Bang
Matthew Smith - at Seeking Alpha - Mon Jan 12, 9:13AM CST

ABC: 90.93 (-2.07), FMI: 46.74 (+22.81), MWIV: 190.00 (+14.35), GILD: 101.21 (-1.00), SHPG: 209.10 (-8.39), TKMR: 24.68 (+8.98), NPSP: 45.35 (+3.44), ABBV: 65.76 (-0.02)

Tekmira teams up with OnCore to focus on hepatitis B cure
By The Associated Press - AP - Mon Jan 12, 8:52AM CST
Shares of Tekmira Pharmaceuticals soared Monday after the Canadian drugmaker said it would buy privately held OnCore Biopharma to form a team focused on developing a hepatitis B cure.
GILD: 101.21 (-1.00), TKMR: 24.68 (+8.98), TKM.TO: 29.38 (+10.55)

My Predictions For 2015 - Final Chapter
Bret Jensen - at Seeking Alpha - Mon Jan 12, 8:07AM CST

DVAX: 18.58 (+0.87), AGEN: 6.17 (+0.88), GILD: 101.21 (-1.00), GBX: 50.61 (-2.15), AAPL: 109.25 (-2.76)

1 Big Loser in the Slugfest Between AbbVie and Gilead Sciences
Keith Speights, The Motley Fool - Motley Fool - Mon Jan 12, 8:03AM CST
Source: Wikimedia Commons An epic fight is under way in the world of hepatitis C. We've seen a couple of punches thrown just over the last few days. The latest occurred on Thursday with Anthem 's selection of Gilead Sciences ' Harvoni as a...
ANTM: 128.83 (-0.97), ESRX: 83.08 (-1.82), CTRX: 49.24 (-0.49), JPM: 58.83 (-0.51), GILD: 101.21 (-1.00), CVS: 97.20 (-0.72), ABBV: 65.76 (-0.02), MS: 36.37 (-0.51)

Which Big Biotech Will Soar in 2015?
Motley Fool Staff - Motley Fool - Mon Jan 12, 7:59AM CST
In a bid to help investors identify the biotech companies that could be top stocks this year, we asked three top Motley Fool contributors to tell us which biotech stocks they think could head significantly higher in 2015. Read on to learn which...
BIIB: 347.84 (+5.50), ESRX: 83.08 (-1.82), GILD: 101.21 (-1.00), ABBV: 65.76 (-0.02), CELG: 117.00 (+3.33)

Is Celgene Corporation a Takeover Target in 2015?
George Budwell, The Motley Fool - Motley Fool - Mon Jan 12, 6:30AM CST
Source: Celgene. The pharmaceutical industry underwent a major consolidation last year, driven by the loss of former top-selling drugs to the patent cliff, huge cash positions built up over the preceding decade, and an innovation boom that has made...
BLUE: 101.95 (-1.68), GILD: 101.21 (-1.00), PFE: 32.77 (+0.12), GSK: 42.93 (+0.13), BMY: 62.18 (+1.86), CELG: 117.00 (+3.33)

Should AbbVie Inc. Or Gilead Sciences Buy These Tiny Biotech Stocks?
Todd Campbell, The Motley Fool - Motley Fool - Sun Jan 11, 12:04PM CST
Recently approved new drugs from AbbVie and Gilead Sciences means that the two biotech titans are locked in a heated battle for hepatitis C market share, but these companies may be better served shifting their attention away from this tussle...
ESRX: 83.08 (-1.82), ISIS: 73.34 (+1.08), ALNY: 103.78 (+2.48), GILD: 101.21 (-1.00), ACHN: 14.64 (+0.08), RGLS: 18.90 (-0.43), ABBV: 65.76 (-0.02)

Better Healthcare Buy: Big or Little Biotechs
Motley Fool Staff - Motley Fool - Sun Jan 11, 11:32AM CST
Source: Flickr user Chris Potter Biotechnology stocks were among the market's top performers in 2014, but biotech stocks were also among the market's riskiest plays. For risk tolerant investors, biotech's pop-and-drop nature may be enticing, but...
BIIB: 347.84 (+5.50), GILD: 101.21 (-1.00)

5 Predictions for Biotechnology Stocks in 2015
Todd Campbell, The Motley Fool - Motley Fool - Sun Jan 11, 10:02AM CST
Biotechnology was one of the market's shining stars in 2014. The Nasdaq Biotechnology Index ETF returned an impressive 33% last year, significantly outpacing the performance of the S&P 500. Of course, no one can know if biotechnology stocks will...
BLUE: 101.95 (-1.68), ACT: 272.28 (+3.60), AMGN: 156.22 (+0.49), RGLS: 18.90 (-0.43), EPZM: 17.49 (+0.01), ALKS: 68.61 (+3.47), HSP: 61.55 (-0.09), CELG: 117.00 (+3.33), JNJ: 104.58 (-0.36), ESRX: 83.08 (-1.82), GILD: 101.21 (-1.00), GWPH: 78.73 (+0.20), ACHN: 14.64 (+0.08), MRK: 62.30 (-0.26), ABBV: 65.76 (-0.02), AGIO: 131.55 (+3.43), XLRN: 40.89 (-0.25), NVS: 95.48 (-0.64)

3 Ways Gilead Sciences, Inc. Could Still Be in Big Trouble
Sean Williams, The Motley Fool - Motley Fool - Sun Jan 11, 8:02AM CST
Arguably no biotech stock thrilled investors in 2014 more than Gilead Sciences . Gilead finished the year up 26%, about double the performance of the broad-market indexes, and the approval and exceptional launch of hepatitis C drugs Sovaldi and...
VRTX: 118.31 (-3.90), ESRX: 83.08 (-1.82), GILD: 101.21 (-1.00), MRK: 62.30 (-0.26), AZN: 70.79 (+1.35), ABBV: 65.76 (-0.02)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

FDA Greenlights VELO: A Turning Point for Reynolds?

FDA Decision: A Big Win for Reynolds American Boy, am I seeing a shift in the winds. The FDA's green light for VELO nicotine pouches adds a fresh feather to Reynolds American's cap. In a gritty industry like tobacco, getting FDA's nod ain't just about safety; it’s a strategic leg up against traditional smoke. My gut tells me this isn't just about keeping pace. It's...

AstroRad Vest Makes Spaceflight History at Smithsonian

Space Gear Finds a New Home In a move that brings a piece of the cosmos down to Earth, the AstroRad radiation protection vest, used by astronauts aboard the International Space Station (ISS), has landed a spot in the Smithsonian's National Air and Space Museum. It's not just some random hunk of tech; this vest represents a milestone in the annals of space gear — a...

Standards Touch 2027 Student Paper Competition

Diving into Trust: ANSI's 2027 Paper Challenge Out from the buzz of New York, the American National Standards Institute (ANSI) has stirred up some real brain-teasing talk for students across the country. Kicking off the 2027 Student Paper Competition, they're handing students a chance to ponder a question we take for granted every day. Do we ever truly consider what makes...

Richmond Mutual's Q3 2026: A Merger's Mixed Impact

Third Quarter Reflections: Big Changes, Mixed Results Alright, Richmond Mutual Bancorporation just dropped their third quarter results for 2026 and let's just say, it's got more layers than an onion. Richmond's the parent of First Bank Midwest, and their latest numbers tell a tale of a merger aftermath with Farmers Bancorp. They've pulled off a balance sheet expansion,...

How Dental Cleaning Frequency Boosts Oral Health

Cleaning Up Confusion on Dental Visits Never thought I'd be waxing poetic about gum health, but here we are. You know what they say, ain't no business like show business—and today's show is all about the pearly whites context, courtesy of Dr. Calvin Despain over in Moses Lake, Washington. Apparently, keeping that grin free from plaque isn't as simple as a quick brush...

Tradier Brokerage Data Breach Sparks Legal Probe

Data Breach Drama Hits Tradier Brokerage Picture a broker-dealer like Tradier Brokerage, out in Charlotte, getting its customers' details hanging out there for the world to see. A calamity, courtesy of a cyberattack on their third-party vendor, Etna Software Corp. And we're talking Social Security numbers, tax IDs—emails across Texas and Massachusetts were popping up...

Novelis Readies for Q2 Earnings Amid Global Market Focus

Amid the ever-turbulent waves of industrial demand and environmental expectations, Novelis Inc. is set to lay bare its fiscal cards for Q2 of 2027. Circle November 5 on your calendar—this is when Steve Fisher and Dev Ahuja aim to sift through the heaps, scrutinize numbers, and spell out their game plan for investors via a conference call. Get your coffee ready for this...

ANTHBOT N8 Wins Honors: A New Era in Lawn Care?

Rising Above the Grass Well, here's a twist: ANTHBOT's latest robot mower, the N8, caught the eyes of TIME magazine and snagged a spot on their Best Inventions of 2026 list. A lawnmower? You bet. And not just any lawnmower—this one's doing a whole song and dance with its 4-in-1 approach that'll make any garden-owning homeowner's life simpler. Kudos to them for shaking...

Apollo Scooters Reveal the Truth About Winter Range Loss

When the mercury dips, how far can your electric scooter really take you? Apollo Scooters has put some meat on the bones of this question, digging through over half a million rides to bust the myth that chillier days chop your scooter's range by half. Reality Check on Winter Range Loss For years, folks have griped that cold weather slashes electric vehicle range by a...

BAILOR Welcomes Co-Founder Bob Bailor to Coach Academy

A New Chapter for a Seasoned Entrepreneur There's a certain irony in a seasoned business vet stepping into a new role at his own daughter's company, and that's exactly what's unfolding with the Bailors. Huntsville's own BAILOR isn't just another growth strategy company; it's the embodiment of a father-daughter dream team. After years as the ordinary head honcho, Bob...